BP&Food

Eli Lilly Suzhou Pharmaceutical Co., Ltd. is Eli Lilly and Company’s wholly owned pharmaceutical company in China. It is committed to continuous innovation, the pursuit of excellence and high-quality manufacturing, as long as the medicines with the red Lilly logo are of high quality. Lilly's two capital increases and the expansion of its manufacturing facilities in China within five years demonstrate its commitment to China and its strong confidence in the world's largest pharmaceutical market of the future.

Beijing Tiantan Biological Products Co.,Ltd is a leading provider of vaccines, blood preparations, diagnostic supplies and other biological products. With a portfolio of over 20 varieties of leading products, including the recombinant yeast hepatitis B vaccine, the company is a major player in the global healthcare sector. These include the hepatitis B vaccine, rubella vaccine, polio vaccine, encephalitis B inactivated vaccine, leprosy duplicate vaccine (MR), and various diagnostic reagents. The company's products enjoy a market share of over 50% in China, and all its production facilities have passed the GMP certification of the State Food and Drug Administration (SFDA). The company's main production workshops are at the international advanced level. The company's H1N1 influenza vaccine has been collected by the state.

Shanghai Obio Precision Medicine Industrial Park opened in Shanghai Lingang. With a total investment of approximately 1.5 billion RMB, a total floor area of approximately 77,000 square meters, and a maximum reactor size of up to 2,000L. Shanghai Obio Precision Medicine Industrial Park is a rarely-seen single-gene cell therapy commercial production and service base in the world, which can continue to provide one-stop CRO/CDMO solutions from DNA to NDA for the global gene and cell therapy industry, to better meet the rapidly growing demand for gene therapy CDMO, and continue to empower the industry chain.

As an innovative pharmaceutical group engaged in the research, development, production and sales of pharmaceutical innovations and high-quality medicines, and a core enterprise of Hong Kong-listed China Biopharmaceutical (01177. HK) Chia-Tai Tianqing Pharmaceutical Company is committed to providing patients with better health solutions and high-quality, affordable pharmaceutical resources. It is a well-known research and development and production base of anti-tumour and liver disease medicines, and a key backbone enterprise of the Lianyungang New Pharmaceutical Industrial Base of the National Torch Program. In 2023, it was ranked 12th in the list of top 100 enterprises in China's pharmaceutical industry. In 2024, it was named the best industrial enterprise in China's pharmaceutical R&D product line.

Sichuan Swellfun Co Ltd. (a listed company) is one of the large-scale high-quality liquor producers in China, with its enterprise scale and efficiency ranking at the forefront of the industry.

The Nanjing GenScript Biotech Corporation plant project, with a total investment of 1 billion yuan, commenced construction in April 2022. The project encompasses an area of approximately 10,000 square meters, with a building area of 30,200 square meters. Upon completion of the initial phase, the plant will be transformed into a state-of-the-art facility, serving as both a central warehouse and a hub for scientific research and production.